In vitro tests reveal significant inhibition of cell proliferation in colorectal, glioblastoma, and prostate cancer cells, indicating potential for amentoflavone as a natural cancer treatment.
Amentoflavone, a biflavonoid found in plants of the Ochnaceae family, was studied for its potential in treating colorectal, glioblastoma, and prostate cancer in vitro experimental models. Tests on human tumour cells HCT-116, SNB-19, and PC-3 showed significant inhibition of cell proliferation by amentoflavone, notably 95.60% inhibition and an IC50 of 0.675 ± 0.26 µM in HCT-116 cells. Computational studies indicated that amentoflavone interacts significantly with the active site of the CDK2 protein, comparable to the inhibitor kenpaullone, a reference compound in oncology research. Furthermore, agathisflavone an isomer of amentoflavone, exhibited the strongest interaction with CDK2 protein, with a binding energy of -10.3 kcal/mol, being very close to the positive control sorafenib (-10.6 kcal/mol). These findings underscore the therapeutic potential of amentoflavone and the ongoing importance of researching natural compounds for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Frota et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: